iv semaglutide Wegovy® 0.25 mg / 0.5 mL Injection 4 Semaglutide & Tirzepatide for Weight

Program Structure And Accountability How a program is structured directly affects patient adherence and outcomes

Frequent injection can be burdensome for patients even if treated once weekly

Whenever possible, work within a laminar flow hood to maintain sterility

Each injection remains 3.2 mg while frequency falls

Since GLP-1 medication is a non-surgical treatment, theres no downtime or recovery period

The ability of eNOS produced NO to prevent platelet adhesion and aggregation reduces the propensity for the development of abnormal fibrin clots (thrombi) and, therefore, will contribute to a reduced potential for the development of atherosclerosis